Combination therapy using GPX4 inhibitors and immunotherapy can further activate T cell infiltration in the tumor microenvironment (TME), and its clinical efficacy is significantly superior to that of monotherapy, indicating its potential as a novel precision medicine strategy in LAR-type TNBC [13]. This evidence concerns the gene GPX4 and neoplasm.